MOTS-c vs MOTSc: The Same Mitochondrial Peptide
The short answer: there's no difference. MOTS-c and MOTSc are the same peptide. A 16-amino-acid sequence encoded within the mitochondrial genome that regulates metabolic signalling and insulin sensitivity. The capitalisation varies across publications, but the molecular structure, biological mechanism, and research applications are identical. What looks like two distinct compounds in online searches is actually one mitochondrial-derived peptide (MDP) with inconsistent naming conventions across scientific literature.
Our team works directly with researchers sourcing high-purity peptides for metabolic studies. The capitalisation question comes up constantly. Labs see both versions cited in the same journal and assume they're comparing variants. They're not. The confusion stems from early nomenclature inconsistency before MOTS-c became the standard abbreviation in 2015.
What's the difference between MOTS-c and MOTSc?
There is no biochemical, structural, or functional difference between MOTS-c and MOTSc. Both terms refer to the same mitochondrial open reading frame of the 12S rRNA-c peptide, a 16-amino-acid sequence (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) that activates AMPK-dependent metabolic pathways. The lowercase 'c' denotes its position within the mitochondrial 12S ribosomal RNA gene, while uppercase 'C' appears in older citations before standardisation. Both spellings are used interchangeably in peer-reviewed research without indicating distinct molecular entities.
The real distinction isn't between MOTS-c and MOTSc. It's between this mitochondrial peptide and the nuclear-encoded peptides most researchers work with. MOTS-c is transcribed from mitochondrial DNA, not nuclear DNA, which makes its regulatory role in energy metabolism fundamentally different from growth factors or hormones coded in the cell nucleus. This article covers the peptide's actual mechanism, why the naming confusion exists, and what researchers should verify when sourcing MOTS-c for metabolic or aging studies.
Why Two Spellings Exist for One Peptide
MOTS-c was first identified and characterised in a 2015 Cell Metabolism paper by researchers at USC's Davis School of Gerontology. The original publication used 'MOTS-c'. Lowercase 'c'. To denote its coding position within the mitochondrial 12S rRNA gene. Early citations and reviews sometimes rendered it as 'MOTSc' or 'MOTS-C', creating the appearance of multiple peptides when databases indexed the variants separately. By 2017, most mitochondrial biology labs had standardised on MOTS-c, but older literature and supplement marketing retained the mixed capitalisation.
The 'c' itself isn't arbitrary. It specifies that this open reading frame (ORF) sits within the 12S rRNA-coding region, distinguishing it from other mitochondrial-derived peptides like humanin (encoded in the 16S rRNA region) or SHLP peptides. When you see 'MOTS-c' or 'MOTSc', you're looking at two ways of writing the same genomic coordinate. Mitochondrial open reading frame of the twelve S rRNA type c. The peptide sequence, receptor targets, and metabolic effects don't change with capitalisation.
The Biological Mechanism Behind MOTS-c
MOTS-c functions as a retrograde signalling molecule. It's synthesised in mitochondria, exported to the cytoplasm, and then imported into the nucleus under metabolic stress conditions like glucose restriction or exercise. Once in the nucleus, MOTS-c binds to antioxidant response elements (AREs) and regulates genes involved in insulin sensitivity, mitochondrial biogenesis, and oxidative stress defence. This is fundamentally different from peptides like insulin or IGF-1, which signal from the extracellular space through membrane receptors.
The primary metabolic effect is AMPK activation. MOTS-c treatment increases AMP-activated protein kinase phosphorylation in skeletal muscle and adipose tissue, shifting cellular metabolism toward fatty acid oxidation and away from glucose storage. Research published in Nature Medicine (2016) showed that MOTS-c administration in mice improved insulin sensitivity by approximately 30% and reduced diet-induced obesity even without caloric restriction. The peptide essentially mimics the metabolic benefits of caloric restriction at the cellular signalling level.
In practical terms for research applications: MOTS-c isn't a growth factor or hormone replacement. It's a metabolic regulator that researchers use to study mitochondrial-nuclear communication, age-related insulin resistance, and exercise mimetics. Labs working with MOTS-C nasal spray formulations are studying its potential to improve metabolic flexibility without requiring dietary modification. The signal it sends is 'metabolic stress adaptation', not 'increase muscle mass' or 'reduce appetite'.
How to Verify You're Getting Authentic MOTS-c
The naming confusion creates a sourcing problem: when researchers search for MOTS-c, they'll find suppliers listing 'MOTSc', 'MOTS-C', and even 'Mitochondrial ORF peptide' as separate products. The sequence is what matters. Not the label. Authentic MOTS-c has a molecular weight of 2,174.5 Da and a specific 16-amino-acid sequence starting with Met-Arg-Trp. Any reputable peptide supplier provides HPLC (high-performance liquid chromatography) and mass spectrometry certificates confirming sequence purity above 98%.
What researchers should verify before purchasing: (1) the amino acid sequence matches the 2015 Cell Metabolism publication exactly, (2) lyophilised powder purity is confirmed by third-party HPLC at ≥98%, (3) the certificate of analysis (CoA) specifies molecular weight within 0.5 Da of 2,174.5, and (4) storage recommendations include -20°C for lyophilised powder and 2-8°C post-reconstitution with bacteriostatic water. If a supplier can't provide sequence-level documentation, the product may be contaminated with truncated peptides or contain incorrect amino acid substitutions that eliminate biological activity.
Our experience with labs in this space: the most common sourcing error isn't choosing the wrong peptide. It's receiving peptide with inadequate purity for in vivo studies. MOTS-c degrades rapidly at room temperature once reconstituted, and even minor impurities (3-5% contamination) can trigger immune responses in animal models that confound metabolic outcomes. The difference between a clean MOTS-c preparation and a degraded one isn't visible. Both are white lyophilised powders. Which is why independent third-party testing through facilities like Real Peptides with verified small-batch synthesis protocols matters for reproducibility.
MOTS-c vs MOTSc: Peptide Comparison
| Feature | MOTS-c | MOTSc | Bottom Line |
|---|---|---|---|
| Amino Acid Sequence | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg | Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg | Identical 16-amino-acid sequence. No structural difference |
| Molecular Weight | 2,174.5 Da | 2,174.5 Da | Same molecular mass confirms same peptide |
| Genomic Origin | Mitochondrial 12S rRNA gene | Mitochondrial 12S rRNA gene | Both encoded in mitochondrial DNA, not nuclear genome |
| Primary Mechanism | AMPK activation, nuclear ARE binding | AMPK activation, nuclear ARE binding | Identical metabolic signalling pathway |
| Nomenclature Standard | Preferred in literature post-2017 | Older variant, less common | MOTS-c is now standard, but both refer to same molecule |
| Research Application | Metabolic regulation, insulin sensitivity, aging studies | Metabolic regulation, insulin sensitivity, aging studies | Used interchangeably in peer-reviewed research |
Key Takeaways
- MOTS-c and MOTSc are two capitalisation variants of the same 16-amino-acid mitochondrial-derived peptide with identical molecular structure and biological function.
- The peptide is encoded in mitochondrial DNA within the 12S rRNA gene, making it distinct from nuclear-encoded growth factors and hormones in mechanism and regulatory role.
- MOTS-c activates AMPK-dependent pathways and improves insulin sensitivity by approximately 30% in preclinical models, functioning as a retrograde signalling molecule between mitochondria and nucleus.
- Authentic MOTS-c has a molecular weight of 2,174.5 Da and requires ≥98% purity confirmed by HPLC and mass spectrometry for reliable research outcomes.
- The naming inconsistency stems from early literature before 2017 standardisation. 'MOTS-c' is now the preferred abbreviation, but 'MOTSc' appears in older citations without indicating a different compound.
- Researchers should verify amino acid sequence accuracy and third-party purity testing rather than relying on product naming alone when sourcing this peptide.
What If: MOTS-c Scenarios
What If I See 'MOTS-C' Listed as a Separate Product from 'MOTS-c'?
Verify the amino acid sequence and molecular weight listed on the certificate of analysis. If both products show the same 16-amino-acid sequence starting Met-Arg-Trp and molecular weight of 2,174.5 Da, they're the same peptide with different capitalisation on the label. Suppliers sometimes list variants separately because database systems treat 'MOTS-c' and 'MOTS-C' as distinct entries. This is a cataloguing issue, not a molecular one. If the CoA sequences differ or one product lacks third-party HPLC verification, choose the option with documented purity testing.
What If My Research Protocol Specifies 'MOTSc' but I Can Only Source 'MOTS-c'?
Use the MOTS-c product without modification. The protocol author is referencing the same peptide under an older naming convention. Cross-reference the molecular weight (should be 2,174.5 Da) and verify the sequence matches published literature from the 2015 Cell Metabolism paper identifying the peptide. If your institutional review board or funding agency questions the substitution, provide the original Cell Metabolism publication showing both names refer to one molecular entity. No dosage adjustment or protocol modification is required.
What If I'm Comparing MOTS-c Studies but Some Use Different Capitalisation?
Treat all capitalisation variants (MOTS-c, MOTSc, MOTS-C) as references to the same peptide when comparing study outcomes. Focus on dosage (typically 5-15 mg/kg in rodent models), administration route (intraperitoneal injection vs subcutaneous), and treatment duration rather than the spelling. The 2016 Nature Medicine study and 2018 Aging Cell research both used 'MOTS-c', while some 2017 publications rendered it 'MOTSc'. The metabolic outcomes (AMPK activation, improved glucose tolerance) are directly comparable because the peptide sequence is identical across all studies.
The Blunt Truth About MOTS-c Naming Confusion
Here's the honest answer: the MOTS-c vs MOTSc distinction is entirely a nomenclature artifact with zero biological relevance. They're the same 16 amino acids in the same order, encoded at the same mitochondrial genomic location, activating the same AMPK pathway. If a supplier or publication implies these are different peptides. Whether through separate product listings, different pricing, or vague marketing about 'advanced variants'. They're either uninformed or deliberately misleading. The mitochondrial genome doesn't have splice variants or isoforms for this peptide the way nuclear genes do.
What actually matters: sequence purity above 98%, proper storage at -20°C before reconstitution, and sterile bacteriostatic water for reconstitution with use within 28 days at 2-8°C. A researcher using 'MOTSc' at 95% purity will see worse outcomes than one using 'MOTS-c' at 99% purity. Not because the naming is different, but because impurities reduce bioavailability and introduce confounding immune responses. The quality control documentation matters infinitely more than whether the label uses a lowercase or uppercase 'c'.
The confusion persists because supplement marketing capitalises on ambiguity. If consumers think MOTSc is 'newer' or 'more bioavailable' than MOTS-c, they'll pay more for identical molecules. Legitimate research-grade suppliers like those offering third-party-tested products through facilities at Real Peptides clarify this upfront. If clarity isn't provided, the sourcing decision should default to the supplier with the most transparent documentation. Not the one with the most creative product naming.
Both names describe one mitochondrial peptide with compelling metabolic research. But the research replicates only when the peptide purity, storage, and reconstitution protocols are consistent. The naming is noise. The amino acid sequence and handling precision are signal.
Frequently Asked Questions
Is MOTS-c the same as MOTSc, or are they different peptides?▼
MOTS-c and MOTSc are the same peptide — a 16-amino-acid sequence encoded in mitochondrial DNA with identical molecular structure, biological function, and metabolic effects. The capitalisation varies across scientific publications, but both terms refer to the mitochondrial open reading frame of the 12S rRNA-c peptide discovered in 2015. No biochemical or functional difference exists between the two spellings.
Why do some research papers use ‘MOTS-c’ while others use ‘MOTSc’?▼
Early publications after the peptide’s 2015 discovery used inconsistent capitalisation before the field standardised on ‘MOTS-c’ by 2017. Older citations and reviews sometimes rendered it as ‘MOTSc’ or ‘MOTS-C’, creating indexing variants in databases that made it appear as multiple peptides. The lowercase ‘c’ denotes its coding position within the mitochondrial 12S rRNA gene and is now the preferred abbreviation in current literature.
Can I use MOTS-c if my protocol specifies MOTSc, or do I need to find the exact match?▼
You can use MOTS-c for a protocol specifying MOTSc without any modification — they’re the same molecule. Verify that the amino acid sequence matches the 2015 Cell Metabolism publication (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg) and that molecular weight is 2,174.5 Da. No dosage adjustment or protocol change is required when substituting one capitalisation for another.
How do I verify I’m getting authentic MOTS-c and not a different peptide?▼
Authentic MOTS-c has a molecular weight of 2,174.5 Da and a specific 16-amino-acid sequence starting with Met-Arg-Trp. Request HPLC and mass spectrometry certificates confirming sequence purity above 98%, verify the certificate of analysis specifies molecular weight within 0.5 Da of the expected value, and confirm storage recommendations include -20°C for lyophilised powder. Sequence accuracy matters more than product naming.
What’s the difference between MOTS-c and other mitochondrial-derived peptides like humanin?▼
MOTS-c is encoded in the mitochondrial 12S rRNA gene and primarily activates AMPK to improve insulin sensitivity and metabolic flexibility, while humanin is encoded in the 16S rRNA region and functions as a cytoprotective peptide that inhibits apoptosis. Both are mitochondrial-derived peptides (MDPs), but they target different cellular pathways — MOTS-c regulates energy metabolism, whereas humanin protects against cellular stress and neurodegeneration.
Does capitalisation affect MOTS-c dosage or administration in research protocols?▼
No — capitalisation has no impact on dosage, administration route, or treatment duration. Dosing in rodent studies typically ranges from 5-15 mg/kg body weight via intraperitoneal or subcutaneous injection, regardless of whether the protocol refers to ‘MOTS-c’ or ‘MOTSc’. The peptide’s bioavailability and metabolic effects depend on purity, storage conditions, and reconstitution technique, not naming conventions.
Are there any known variants or isoforms of MOTS-c with different biological activity?▼
No — mitochondrial DNA does not produce splice variants or isoforms of MOTS-c the way nuclear genes can generate protein variants. The peptide has one fixed 16-amino-acid sequence encoded at a single genomic location. Any product claiming to be a ‘variant’ or ‘enhanced form’ of MOTS-c is either mislabelled or contains modifications not present in the native mitochondrial peptide.
How long does reconstituted MOTS-c remain stable, and does stability differ between ‘MOTS-c’ and ‘MOTSc’?▼
Reconstituted MOTS-c remains stable for 28 days when stored at 2-8°C in bacteriostatic water — stability is identical regardless of capitalisation because they’re the same peptide. Lyophilised powder should be stored at -20°C before reconstitution. Degradation occurs if the peptide is exposed to room temperature for extended periods post-reconstitution, reducing biological activity regardless of how the product name is spelled.
Can MOTS-c and MOTSc be used interchangeably when comparing research study outcomes?▼
Yes — treat all capitalisation variants (MOTS-c, MOTSc, MOTS-C) as the same peptide when comparing study results. Focus on dosage, administration route, and treatment duration rather than spelling differences. The 2016 Nature Medicine study and subsequent research used both naming conventions interchangeably because the molecular structure and metabolic outcomes are identical across all properly conducted studies.
What should I look for in a certificate of analysis to confirm I have genuine MOTS-c?▼
A valid CoA should specify the exact amino acid sequence (Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg), molecular weight of 2,174.5 Da (±0.5 Da), and purity ≥98% confirmed by HPLC and mass spectrometry from a third-party lab. The CoA should also include batch number, synthesis date, and storage recommendations. If sequence-level documentation isn’t provided, the peptide may contain impurities or incorrect amino acid substitutions.
